MEDIPOST Announces the Exclusive Commercialization License Agreement with Teikoku Seiyaku for Knee Osteoarthritis Treatment CARTISTEM® in Japan

Antonio Seung Jin Lee, Head of MEDIPOST's Global Business Division and Co-CEO of MEDIPOST, Inc. & Akira Nakagawa, Board Member & Senior Managing Director, International Business

- South Korean biotech company secures US$8 million in upfront payment for the joint commercialization of the stem cell therapy CARTISTEM® targeting the Japanese knee osteoarthritis market.

SEOUL, South Korea, Dec. 19, 2025 /PRNewswire/ -- MEDIPOST Co., Ltd. (KOSDAQ 078160), a fully integrated cell therapy biotechnology company, today announced a multi-year partnership with Japan's Teikoku Seiyaku Co., Ltd. for the commercialization of CARTISTEM®, an innovative treatment for knee osteoarthritis, in the Japanese market.

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.